Gaois

Similar terms:

This is a static copy of data that is exported from IATE on an occasional basis. It should not be assumed that information provided about an entry here will always correspond to the current version of the entry in IATE. That current version can be checked by clicking on the link on the upper right hand side of each entry. More information »

1 result

  1. SOCIAL QUESTIONS|health|pharmaceutical industry · PRODUCTION, TECHNOLOGY AND RESEARCH|research and intellectual property|research
    ceadúnú forchéimnitheach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    adaptive licensing | AL | progressive licensing | staggered approval | managed entry | adaptive approval | progressive authorization
    en
    Definition authorisation of human medicines based on a prospectively-planned process, starting with the early authorisation of a medicine in a restricted patient population, followed by iterative phases of evidence-gathering and the adaptation of the marketing authorisation to allow broader patient populations to access the medicine Reference "European Medicines Agency, Adaptive licensing http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp [28.11.2014]"
    Comment Adaptive licensing is particularly relevant for medicines with the potential to treat serious conditions where there is an unmet medical need. This approach is intended to maximise the positive impact of new medicines on public health by balancing the need for timely patient access with the importance of providing adequate, evolving information on a medicine's benefits and risks.
    autorisation progressive | autorisation progressive de mise sur le marché | autorisation de mise sur le marché progressive | AMM progressive | adaptive licensing | autorisation adaptative | autorisation graduelle | AMM graduelle | autorisation graduelle de mise sur le marché
    fr
    Definition autorisation de mise sur le marché d'un médicament permettant, dans un premier temps, l'accès précoce à ce médicament pour un nombre limité de patients, puis l'élargissement progressif à des populations de patients plus importantes en fonction du résultat des évaluations et de la surveillance et des informations recueillies Reference "Conseil-FR, d'après le site de l'Agence nationale de sécurité du médicament et des produits de santé (ANSM), ""Les 1ères Rencontres de l’ANSM sous le signe de l’innovation et de la surveillance "", 8.10.2014, http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Les-1eres-Rencontres-de-l-ANSM-sous-le-signe-de-l-innovation-et-de-la-surveillance-Point-d-information et [2.12.2014]"